CP

Convert Pharmaceuticals

BE0671.828.631

Gross margin
€ -248K ↑ 52% 2025 Total € -239K
Profit
€ -629K ↑ 3% 2025 Total € -4.21M
EBITDA
€ -248K ↑ 52% 2025 Total € -1.19M
EBIT
€ -549K ↑ 26% 2025 Total € -7.69M
Net profit
€ -629K ↑ 3% 2025 Total € -4.21M
Capex
€ 1.89M 2018
Assets
€ 941K ↓ 23% 2025
Equity
€ -842K ↑ 28% 2025
Debt
€ 1.78M ↓ 25% 2025
Cash
€ 158K ↓ 71% 2025
Cashflow
€ -328K ↑ 22% 2025 Total € 2.28M
Working capital
€ -102K ↓ 141% 2025
Current ratio
0.63 ↓ 65% 2025
Quick ratio
0.63 ↑ 123% 2025
Working capital ratio
0.63 ↓ 94% 2025
Debt
€ 1.78M ↓ 25% 2025
Short-term debt
€ 278K ↑ 412% 2025
Long-term debt
€ 1.51M ↓ 27% 2025
Debt / EBITDA
311 ↑ 619% 2022
Solvability
-89.4% ↑ 6.3 pt 2025
Long term debt ratio
-1.79 ↓ 1% 2025
Gross profitability
39.0% ↑ 2.8 pt 2025
Net profitability
74.8% ↑ 19.3 pt 2025
Return On Assets (ROA)
-66.87 ↓ 26% 2025
Return On Equity (ROE)
74.76 ↑ 35% 2025
Taxes
€ 1K ↓ 16% 2022 Total € 3K
Salaries and Social Security Contributions
€ 5K ↓ 86% 2022 Total € 57K
Employees
0.30 2023
Staff cost per employee
€ 18K ↑ 112% 2022